Hiroki Inada

11PUBLICATIONS
26CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Disease surveillanceMolecular targetsTissue engineering
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 26, 2026
Letter: Interpretation of Cognitive and Clinical Outcomes in the Randomized Trial of Rifaximin for Covert Hepatic Encephalopathy. Authors' Reply.

|Jul 13, 2026
Editorial: Rifaximin and the Gut-Liver-Brain Axis-Progress and Prudence. Authors' Reply.

|Jul 06, 2026
Statin Use Is Associated With Improved Survival But Not Progression-Free Outcomes in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab.

|May 06, 2026
Rifaximin Improves Cognitive Performance and Reduces Cirrhosis-Related Adverse Events in Covert Hepatic Encephalopathy: A Randomized Controlled Trial.

|Mar 18, 2026
Impact of Etiological Shifts and the Rising Burden of Non-B Non-C Hepatocellular Carcinoma on Surveillance and Prognosis: Insights From a 20-Year Retrospective Observational Study.

Yoko Yoshimaru, Katsuya Nagaoka, Hiroko Setoyama

|May 03, 2025
Serum alpha-fetoprotein/hepatocyte growth factor ratio as a novel biomarker predicting the prognosis of acute alcoholic hepatitis.

Hiroki Inada, Katsuya Nagaoka, Kenyu Hashimoto

Pageof 2

Frequent Collaborators

10 joint publications

Yasuhito Tanaka

5 joint publications

Takayuki Tokunaga

4 joint publications

Satoshi Narahara

4 joint publications

Katsuya Nagaoka